基于GPER介导途径探讨隐丹参酮诱导人乳腺癌SKBR-3细胞凋亡的分子机制Molecular mechanism of apoptosis of breast cancer SKBR-3 cells induced by cryptanshinone via G protein coupled estrogen receptor( GPER) mediated pathway
石丹宁;崔丽霞;赵丕文;孙丽萍;陈梦;牛建昭;
摘要(Abstract):
基于G蛋白偶联雌激素受体(GPER)及其介导的PI3K/AKT途径探讨隐丹参酮(cryptotanshinone,CPT)诱导人乳腺癌细胞凋亡的效应及其分子机制。选用核ER阴性、GPER阳性人乳腺癌SKBR-3细胞,采用Annexin V-FITC/PI双染法检测CPT对细胞凋亡率的影响,Western blot法检测CPT对凋亡效应蛋白caspase-3表达的影响; Western blot及免疫荧光技术检测CPT对GPER介导的PI3K/AKT通路上关键蛋白表达的调控效应;同时,为进一步明确GPER介导的PI3K/AKT信号通路在CPT诱导SKBR-3细胞凋亡中的作用,选用GPER特异性激动剂G1、特异性拮抗剂G15及PI3K特异性抑制剂LY294002进行干预。结果显示,5,10μmol·L~(-1)CPT作用48 h后,SKBR-3细胞的凋亡率上升为46. 1%,69. 0%(P<0. 01),caspase-3表达则随着CPT浓度增加而升高(P<0. 01)。PI3K,AKT,p-AKT蛋白表达均可被CPT抑制(P<0. 05或P<0. 01),G1与5μmol·L~(-1)CPT联合作用48 h后可见AKT与p-AKT的表达量进一步降低(P<0. 05),而G15与5μmol·L~(-1)CPT联合作用后AKT与p-AKT表达的下降被明显抑制(P<0. 05); 1μmol·L~(-1)LY294002干预下,可见AKT,p-AKT的表达受到了更为明显的抑制(P <0. 01)。AKT与p-AKT的荧光表达强度同样能够受到CPT抑制,G1,G15,LY294002的干预与Western blot结果一致(P <0. 05或P <0. 01)。此外,CPT对SKBR-3细胞中GPER表达具有一定的抑制效应(P<0. 01),加入G1可相对抑制CPT对GPER表达的下调作用;加入G15可使CPT对GPER表达的抑制作用进一步增强。综上,隐丹参酮可诱导人乳腺癌SKBR-3细胞凋亡,其分子途径可能与隐丹参酮对GPER表达及其介导的PI3K/AKT信号通路的调控作用有关。
关键词(KeyWords): 隐丹参酮;GPER;乳腺癌;SKBR-3;PI3K/AKT;细胞凋亡;植物雌激素
基金项目(Foundation): 国家自然科学基金项目(81673764);; 教育部&国家外国专家局“北京中医药大学中西医结合学科创新引智基地”项目(B07007);; 北京中医药大学研究生自主课题(2018-JYB-XS100);北京中医药大学中央高校基本科研业务费专项(2017-JYB-JS-001)
作者(Author): 石丹宁;崔丽霞;赵丕文;孙丽萍;陈梦;牛建昭;
Email:
参考文献(References):
- [1] Tong C,Wu M,Cho W,et al. Recent advances in the treatment of breast cancer[J]. Front Oncol,2018,8:227.
- [2] Farzaneh S, Zarghi A. Estrogen receptor ligands:s teview(2013—2015)[J]. Sci Pharm,2016,84(3):409.
- [3] Molina L,Figueroa C D,Bhoola K D,et al. GPER-1/GPR30 a novel estrogen receptor sited in the cell membrane:therapeutic coupling to breast cancer[J]. Expert Opin Ther Targets,2017,21(8):755.
- [4]卢迪,赵丕文,赵笛,等.丹参及其有效成分治疗乳腺癌作用机制的研究进展[J].环球中医药,2017(9):1046.
- [5] Chen W Q,Sun K X,Zheng S R,et al. Cancer incidence and mortality in China,2014[J]. Chin J Cancer Res,2018,30(1):1.
- [6] Harbeck N,Gnant M. Breast cancer[J]. Lancet,2017,389(10074):1134.
- [7] Lappano R,Pisano A,Maggiolini M. GPER function in breast cancer:an overview[J]. Front Endocrinol(Lausanne),2014,5:66.
- [8] Pupo M,Maggiolini M,Musti A M. GPER mediates non-genomic effects of estrogen[J]. Methods Mol Biol,2016,1366:471.
- [9]王宝珏,李熠.中医药疗法在乳腺癌治疗应用中的研究进展[J].智慧健康,2018,4(15):39.
- [10]周雍明,崔峰,李军.中药方对乳腺癌内分泌治疗患者生命质量影响的临床研究[J].世界中医药,2018,13(5):1131.
- [11]臧金凤.ER介导丹参酮ⅡA抗妇科肿瘤作用机制的研究[D].北京:北京中医药大学,2016.
- [12]孙艳玲.丹参酮Ⅰ植物雌激素样作用及其机制的研究[D].北京:北京中医药大学,2012.
- [13]赵丕文,臧金凤,陶仕英,等.丹参酮ⅡA抗乳腺癌T47D细胞增殖的GPER途径研究[J].中国药理学通报,2015,31(10):1458.
- [14] Rietjens I,Louisse J,Beekmann K. The potential health effects of dietary phytoestrogens[J]. Br J Pharmacol,2017,174(11):1263.
- [15] Ziaei S,Halaby R. Dietary isoflavones and breast cancer risk[J].Medicines(Basel),2017,4(2):11.
- [16] Zhao P W,Lee D Y,Ma Z Z,et al. The antioxidant effect of carnosol in bovine aortic endothelial cells is mainly mediated via estrogen receptor alpha pathway[J]. Biol Pharm Bull,2012,35(11):1947.
- [17]陈梦,赵丕文,赵笛,等.中药植物雌激素的药理作用研究进展[J].江苏中医药,2017,49(4):82.
- [18]赵元,郑红霞,徐颖,等.中药植物雌激素的研究进展[J].中国中药杂志,2017,42(18):3474.
- [19] Cai Y,Zhang W,Chen Z,et al. Recent insights into the biological activities and drug delivery systems of tanshinones[J]. Int J Nanomedicine,2016,11:121.
- [20] Oche B,Chen L,Ma Y K,et al. Cryptotanshinone and wogonin up-regulate e NOS in vascular endothelial cells via ERalpha and down-regulate i NOS in LPS stimulated vascular smooth muscle cells via ERbeta[J]. Arch Pharm Res,2016,39(2):249.
- [21] Chen W,Lu Y,Chen G,et al. Molecular evidence of cryptotanshinone for treatment and prevention of human cancer[J]. Anticancer Agents Med Chem,2013,13(7):979.
- [22] Jiang G,Liu J,Ren B,et al. Anti-tumor and chemosensitization effects of cryptotanshinone extracted from Salvia miltiorrhiza Bge.on ovarian cancer cells in vitro[J]. J Ethnopharmacol,2017,205:33.
- [23] Hassan M,Watari H,Abualmaaty A,et al. Apoptosis and molecular targeting therapy in cancer[J]. Biomed Res Int,2014,2014:150845.
- [24] Goldar S,Khaniani M S,Derakhshan S M,et al. Molecular mechanisms of apoptosis and roles in cancer development and treatment[J]. Asian Pac J Cancer Prev,2015,16(6):2129.
- [25] Wu H,Che X,Zheng Q,et al. Caspases:a molecular switch node in the crosstalk between autophagy and apoptosis[J]. Int J Biol Sci,2014,10(9):1072.
- [26] Savitskaya M A,Onishchenko G E. Mechanisms of apoptosis[J].Biochemistry(Mosc),2015,80(11):1393.
- [27] Xue M,Ji X,Xue C,et al. Caspase-dependent and caspase-independent induction of apoptosis in breast cancer by fucoidan via the PI3K/AKT/GSK3beta pathway in vivo and in vitro[J]. Biomed Pharmacother,2017,94:898.
- [28] Arun A,Ansari M I,Popli P,et al. New piperidine derivative DTPEP acts as dual-acting anti-breast cancer agent by targeting ERalpha and downregulating PI3K/Akt-PKCalpha leading to caspase-dependent apoptosis[J]. Cell Prolif,2018,51(6):e12501.
- [29] Manning B D,Toker A. AKT/PKB signaling:navigating the network[J]. Cell,2017,169(3):381.
- [30] Guerrero-Zotano A, Mayer I A, Arteaga C L. PI3K/AKT/m TOR:role in breast cancer progression,drug resistance,and treatment[J]. Cancer Metastasis Rev,2016,35(4):515.
- [31] Hsieh C J,Hsu Y L,Huang Y F,et al. Molecular mechanisms of anticancer effects of phytoestrogens in breast cancer[J]. Curr Protein Pept Sci,2018,19(3):323.
- [32] Badinloo M,Esmaeili-Mahani S. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin,vincristine,and etoposide in a panel of cancer cell lines[J].Fundam Clin Pharmacol,2014,28(4):414.
- [33] Park B J,Whichard Z L,Corey S J. Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy[J]. Cancer Lett,2012,320(1):104.
- [34] Yanamandra M,Mitra S,Giri A. Development and application of PI3K assays for novel drug discovery[J]. Expert Opin Drug Discov,2015,10(2):171.
- [35]怀磊.PI3K/AKT/m TOR信号通路特异性抑制剂RAD001和LY294002对不同分子特征人乳腺癌细胞增殖和凋亡的影响[D].乌鲁木齐:新疆医科大学,2015.